QSS
KALV

Quantitative Systematic Strategies’s KalVista Pharmaceuticals KALV Stock Holding History

Quantitative Systematic Strategies’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,910
Closed -$132K – 657
2020
Q2 		$132K Buy
+10,910
New +$116K 0.03% 545
2020
Q1 		– Sell
-12,738
Closed -$227K – 396
2019
Q4 		$227K Buy
+12,738
New +$166K 0.03% 486

Other funds holding KALV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Quantitative Systematic Strategies's KALV Position: Q3 2020 in Review

Quantitative Systematic Strategies sold out of KalVista Pharmaceuticals (KALV) in Q3 2020, closing a stake of 10,910 shares — an estimated $132K sold.

Quantitative Systematic Strategies first reported a position in KALV in Q4 2019 and held it in 2 quarters. The position peaked at $227K in Q4 2019. 63 funds tracked by Wall St. Rank hold KALV as of Q3 2020.

  • Quantitative Systematic Strategies reported no remaining KalVista Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Quantitative Systematic Strategies sold 10,910 KalVista Pharmaceuticals shares in Q3 2020, an estimated $132K.
  • Quantitative Systematic Strategies first reported a position in KalVista Pharmaceuticals in Q4 2019 and held it in 2 quarters.
  • Quantitative Systematic Strategies's KalVista Pharmaceuticals position peaked at $227K in Q4 2019.
  • 63 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2020.

Based on Quantitative Systematic Strategies's 13F filing for Q3 2020, filed 9 Nov 2020.